The analysis on the expression of CCL2 in the synchronous colorectal cancer liver metastasis

doi:10.3877/cma.j.issn.2095-3224.2015.03.07

Abstract

Abstract:

Objective

To investigate the relationship between expression of CCL2 in the primary colorectal cancer and synchronous liver metastasis.

Methods

Clinicopathological data of 197 cases with colorectal cancer from Jan.1999 to Dec.2003 in Department of Abdominal Surgery, Cancer Hospital(Institute), CAMS was retrospectively reviewed.104 cases of colorectal cancer without recurrence in 5 years and 93 cases with synchronous liver metastasis were included.The expression of CCL2 was tested in the paraffin primary tumors by immunohistochemistry.The correlation between liver metastasis and clinicopathological factors including CCL2 was done by univariate and multivariate analysis.

Results

Tumor size, lymph node, CEA and CCL2 were independent factors in multivariate analysis(P<0.05). Liver metastasis risk was 5.828(95% CI: 2.212~15.355)for the high expression of CCL2(P<0.05). Liver metastasis was the only factor related to CCL2 in the relationship analysis, while there was no significance between CCL2 and tumor invasion, lymph node and CEA(P>0.05).

Conclusion

The close relationship of tumor size, lymph node, CEA and CCL2 between synchronous colorectal cancer liver metastasis was confirmed.The mechanism of CCL2 underlies the colorectal liver metastasis maybe different from the other clinicopathological factors.

Key words: Colorectal neoplasm, Neoplasm Metastasis, Chemokine CCL2, Pathology, Clinical

Chun-guang GUO, Qian LIU, Li-chao SUN, Dong-bing ZHAO, Jin-hua TAO, Yang WANG. The analysis on the expression of CCL2 in the synchronous colorectal cancer liver metastasis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2015, 04(03): 254-259.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2015.03.07

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2015/V04/I03/254

Figures/Tables 5

References 20

[1]	Manfredi S, Lepage C, Hatem C, et al.Epidemiology and management of liver metastases from colorectal cancer.Ann Surg, 2006, 244(2): 254-259.
[2]	叶颖江，王杉，武将，等．同时性结直肠癌肝转移的临床病理特征分析．中华胃肠外科杂志，2008，11(3): 208-212.
[3]	Mantke R, Schmidt U, Wolff S, et al.Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics.Results of a German prospective multicentre observational study.Eur J Surg Oncol, 2012, 38(3): 259-265.
[4]	Slesser AA, Georgiou P, Brown G, et al.The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review.Clin Exp Metastasis, 2013, 30(4): 457-470.
[5]	Macedo FIMakarawo T. Colorectal hepatic metastasis: Evolving therapies.World J Hepatol, 2014, 6(7): 453-463.
[6]	Fong Y, Fortner J, Sun RL, et al.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.Ann Surg, 1999, 230(3): 309-318.
[7]	Luster AD.Chemokines-chemotactic cytokines that mediate inflammation.N Engl J Med, 1998, 338(7): 436-445.
[8]	Loberg RD, Ying C, Craig M, et al.Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.Cancer Res, 2007, 67(19): 9417-9424.
[9]	Craig MJ, Loberg RD.CCL2(Monocyte Chemoattractant Protein-1)in cancer bone metastases.Cancer Metastasis Rev, 2006, 25(4): 611-619.
[10]	Berencsi K, Rani P, Zhang T, et al.In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2.J Transl Med, 2011, 9: 33.
[11]	Ding X, Yang DR, Lee SO, et al.TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling.Int J Cancer, 2015, 136(4): 955-964.
[12]	Arabzadeh A, Chan C, Nouvion AL, et al.Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer.Oncogene, 2013, 32(7): 849-860.
[13]	Qian BZ, Li J, Zhang H, et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.Nature, 2011, 475(7355): 222-225.
[14]	Sanford DE, Belt BA, Panni RZ, et al.Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.Clin Cancer Res, 2013, 19(13): 3404-3415.
[15]	Baier PK, Eggstein S, Wolff-Vorbeck G, et al.Chemokines in human colorectal carcinoma.Anticancer Res, 2005, 25(5): 3581-3584.
[16]	Cheadle EJ, Riyad K, Subar D, et al.Eotaxin-2 and colorectal cancer: a potential target for immune therapy.Clin Cancer Res, 2007, 13(19): 5719-5728.
[17]	Bailey C, Negus R, Morris A, et al.Chemokine expression is associated with the accumulation of tumour associated macrophages(TAMs)and progression in human colorectal cancer.Clin Exp Metastasis, 2007, 24(2): 121-130.
[18]	Yang X, Lu P, Ishida Y, et al.Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization.Int J Cancer, 2006, 118(2): 335-345.
[19]	Zhao L, Lim SY, Gordon-Weeks AN, et al.Recruitment of a myeloid cell subset(CD11b/Gr1 mid)via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis.Hepatology, 2013, 57(2): 829-839.
[20]	Kitamura T, Fujishita T, Loetscher P, et al.Inactivation of chemokine(C-C motif)receptor 1(CCR1)suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model.Proc Natl Acad Sci USA, 2010, 107(29): 13063-13068.

临床病理特征		例数	结直肠癌		P值
临床病理特征		例数	对照组	肝转移组	P值
年龄(岁)		197	54.5±12.8	56.9±11.3	0.172
性别		?	?	?	?
?	男	108	52(50.0%)	56(60.2%)	0.150
?	女	89	52(50.0%)	37(39.8%)	?
肿瘤大小(cm)		?	4.8±2.1	6.3±2.4	0.000^*
肿瘤部位		?	?	?	?
?	结肠	88	36(34.6%)	52(55.9%)	0.003^*
?	直肠	109	68(65.4%)	41(44.1%)	?
大体分型		?	?	?	?
?	隆起型	127	77(74.0%)	50(53.8%)	0.003^*
?	浸润型＋溃疡型	70	27(26.0%)	43(46.2%)	?
肿瘤分化		?	?	?	?
?	高分化	16	11(10.6%)	5(5.4%)	0.141
?	中分化	157	84(80.8%)	73(78.5%)	?
?	低分化	24	9(8.7%)	15(16.1%)	?
T分期		?	?	?	?
?	T1-2	22	22(21.2%)	0(0.0%)	0.000^*
?	T3-4	175	82(78.8%)	93(100.0%)	?
淋巴结转移		?	?	?	?
?	否	71	59(56.7%)	12(12.9%)	0.000^*
?	是	126	45(43.3%)	81(87.1%)	?
脉管瘤栓		?	?	?	?
?	否	161	95(91.3%)	66(71.0%)	0.000^*
?	是	36	9(8.7%)	27(29.0%)	?
CEA(μg/L)^#		?	?	?	?
?	≤5	77	60(70.6%)	17(20.7%)	0.000^*
?	>5	90	25(29.4%)	65(79.3%)	?
CCL2		?	?	?	?
?	－	103	72(69.2%)	31(33.3%)	0.000^*
?	＋	94	32(30.8%)	62(66.7%)	?

临床病理特征		例数	结直肠癌		P值
临床病理特征		例数	对照组	肝转移组	P值
年龄(岁)		197	54.5±12.8	56.9±11.3	0.172
性别		?	?	?	?
?	男	108	52(50.0%)	56(60.2%)	0.150
?	女	89	52(50.0%)	37(39.8%)	?
肿瘤大小(cm)		?	4.8±2.1	6.3±2.4	0.000^*
肿瘤部位		?	?	?	?
?	结肠	88	36(34.6%)	52(55.9%)	0.003^*
?	直肠	109	68(65.4%)	41(44.1%)	?
大体分型		?	?	?	?
?	隆起型	127	77(74.0%)	50(53.8%)	0.003^*
?	浸润型＋溃疡型	70	27(26.0%)	43(46.2%)	?
肿瘤分化		?	?	?	?
?	高分化	16	11(10.6%)	5(5.4%)	0.141
?	中分化	157	84(80.8%)	73(78.5%)	?
?	低分化	24	9(8.7%)	15(16.1%)	?
T分期		?	?	?	?
?	T1-2	22	22(21.2%)	0(0.0%)	0.000^*
?	T3-4	175	82(78.8%)	93(100.0%)	?
淋巴结转移		?	?	?	?
?	否	71	59(56.7%)	12(12.9%)	0.000^*
?	是	126	45(43.3%)	81(87.1%)	?
脉管瘤栓		?	?	?	?
?	否	161	95(91.3%)	66(71.0%)	0.000^*
?	是	36	9(8.7%)	27(29.0%)	?
CEA(μg/L)^#		?	?	?	?
?	≤5	77	60(70.6%)	17(20.7%)	0.000^*
?	>5	90	25(29.4%)	65(79.3%)	?
CCL2		?	?	?	?
?	－	103	72(69.2%)	31(33.3%)	0.000^*
?	＋	94	32(30.8%)	62(66.7%)	?

临床病理特征	回归系数	Wald值	P值	OR值	95% CI
肿瘤部位	0.585	1.537	0.215	1.795	0.712-4.528
肿瘤大小	1.294	6.479	0.011^*	3.648	1.347-9.880
大体分型	0.358	0.575	0.448	1.431	0.567-3.611
T分期	9.686	0.000	0.998	16087.257	0.000
淋巴结转移	2.048	14.185	0.000^*	7.752	2.670-22.503
脉管瘤栓	0.134	0.043	0.836	1.144	0.320-4.087
CEA^#	2.046	18.005	0.000*	7.740	3.008-19.917
CCL2表达	1.763	12.714	0.000*	5.828	2.212-15.355

临床病理特征	回归系数	Wald值	P值	OR值	95% CI
肿瘤部位	0.585	1.537	0.215	1.795	0.712-4.528
肿瘤大小	1.294	6.479	0.011^*	3.648	1.347-9.880
大体分型	0.358	0.575	0.448	1.431	0.567-3.611
T分期	9.686	0.000	0.998	16087.257	0.000
淋巴结转移	2.048	14.185	0.000^*	7.752	2.670-22.503
脉管瘤栓	0.134	0.043	0.836	1.144	0.320-4.087
CEA^#	2.046	18.005	0.000*	7.740	3.008-19.917
CCL2表达	1.763	12.714	0.000*	5.828	2.212-15.355

临床病理特征		例数	CCL2表达		P值
临床病理特征		例数	阴性	阳性	P值
年龄(岁)		?	54.43±12.31	56.95±11.88	0.146
性别		?	?	?	?
?	男	108	58(56.3%)	50(53.2%)	0.660
?	女	89	45(43.7%)	44(46.8%)	?
肿瘤大小(cm)		?	5.37±2.34	5.65±2.42	0.407
肿瘤部位		?	?	?	?
?	结肠	88	42(40.8%)	46(48.9%)	0.250
?	直肠	109	61(59.2%)	48(51.1%)	?
大体分型		?	?	?	?
?	隆起型	127	72(69.6%)	55(58.5%)	0.095
?	浸润型＋溃疡型	70	31(30.1%)	39(41.5%)	?
肿瘤分化		?	?	?	?
?	高分化	16	10(9.7%)	6(6.4%)	0.350
?	中分化	157	78(75.7%)	79(84.0%)	?
?	低分化	24	15(14.6%)	9(9.6%)	?
T分期		?	?	?	?
?	T1-2	22	16(15.5%)	6(6.4%)	0.042^*
?	T3-4	175	87(84.5%)	88(93.6%)	?
淋巴结转移		?	?	?	?
?	否	71	47(45.6%)	24(25.5%)	0.003^*
?	是	126	56(54.4%)	70(74.5%)	?
脉管瘤栓		?	?	?	?
?	否	161	88(85.4%)	73(77.7%)	0.185
?	是	36	15(14.6%)	21(22.3%)	?
CEA(μg/L)^#		?	?	?	?
?	≤5	77	48(54.5%)	29(36.7%)	0.021^*
?	>5	90	40(45.5%)	50(63.3%)	?
肝转移		?	?	?	?
?	否	104	72(69.6%)	32(34.0%)	0.000^*
?	是	93	31(30.1%)	62(66.0%)	?

Please choose a citation manager

Content to export